Danaher stock: At 4.58 percent below its Frankfurt close, Danaher stock trades at EUR 202.30

Published on 10/23/2026 at 16:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

TD Cowen set a USD 270 target on October 22, 2026. Danaher stock costs EUR 202.30 on October 23, 2026, down 4.58 percent versus its Frankfurt close.

Analyst target and price move

The target moved from USD 255.00 to USD 270.00 on October 22, 2026.
Third-quarter adjusted earnings per share reached USD 2.11 against USD 1.92 consensus on October 22, 2026.
Danaher stock costs EUR 202.30 at Lang & Schwarz on October 23, 2026 at 4:30 p.m. CEST, 4.58 percent below the Frankfurt close of October 22, 2026.
Danaher had a USD 159.8 billion market value and a P/E ratio of 37.14 on October 23, 2026.

Moderne Life-Sciences-Produktionsanlage mit Bioreaktortanks und Forschern in Schutzkleidung — Danaher Corp. Bioprocessing-Anlage US2358511028 mit Bioreaktoren und Wissenschaftlern in moderner steriler Produktionshalle, Illustration mit AI erstellt.

Danaher Corp. (ISIN US2358511028) was trading at EUR 202.30 at Lang & Schwarz on October 23, 2026 at 4:30 p.m. CEST, down 4.58 percent versus the Frankfurt close of October 22, 2026 at EUR 212.00. TD Cowen analyst Dan Brennan maintained a Buy rating and raised the price target from USD 255.00 to USD 270.00 on October 22, 2026, as Benzinga reported.

TD Cowen lifts target to USD 270

The TD Cowen change puts Danaher among several research firms that raised targets after the latest results. The new USD 270 target is USD 67.70 above the Lang & Schwarz price when compared in the same currency only after conversion, so no euro upside calculation is used here.

JPMorgan also raised its target from USD 250.00 to USD 270.00 and kept an Overweight rating on October 22, 2026, according to MarketBeat. The cluster of target increases provides the clearest investor reference point while the euro quotation remains below its recent Frankfurt level.

Danaher stock below its yearly high

On the NYSE, Danaher was trading at USD 227.36 on October 23, 2026 at 10:33 a.m. EDT. Its USD 160.93 to USD 242.80 52-week range puts the price 6.36 percent below the high. Trading volume was 501,692 shares, while the market capitalization stood at USD 159.8 billion.

The latest reported quarter delivered adjusted earnings of USD 2.11 per share against a USD 1.92 consensus estimate, while revenue reached USD 6.6 billion and rose 8.50 percent year over year on October 22, 2026, according to Benzinga. Danaher also lifted its fiscal 2026 adjusted earnings outlook to USD 8.57 to USD 8.62 per share from USD 8.45 to USD 8.60.

Valuation and peer comparison

Danaher's P/E ratio was 37.14 on October 23, 2026. That valuation sits alongside a healthcare diagnostics and research profile spanning biotechnology, diagnostics and life sciences, with 59,000 employees.

Comparison with peers

Danaher Corporation: down 4.58 percent, P/E 37.14, market capitalization USD 159.8 billion.

Thermo Fisher Scientific: down 0.99 percent, P/E 35.25, market capitalization USD 247.7 billion.

IDEXX Laboratories: down 1.01 percent, P/E 39.75, market capitalization USD 44.2 billion.

Price remains the immediate signal

The euro quotation is the sharper short-term signal than the analyst revisions. Danaher stock was trading at EUR 202.30 at Lang & Schwarz on October 23, 2026 at 4:30 p.m. CEST, 4.58 percent below the Frankfurt close of October 22, 2026 at EUR 212.00. The further course of trading is shown by the continuously updated real-time quote of Danaher stock.